There is growing but limited information on the long term clinical status of aHUS patients who have previously received or are continuing to receive treatment with eculizumab. This study is designed to collect clinical data that will provide insight into the long-term outcomes of patients with aHUS.
Study Type
OBSERVATIONAL
Enrollment
94
TMA complication-free survival
Assess the long term efficacy of eculizumab in patients with aHUS who have previously participated in an eculizumab clinical study.
Time frame: 5 Years
Duration of response, change over time of value for platelets, LDH, eGFR, Hgb, TMA intervention
Assess the long term safety of eculizumab in patients with aHUS who have previously participated in an eculizumab clinical study by collecting data on serious adverse events and targeted adverse events.
Time frame: 5 Years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Emory Healthcare - Children's Center
Atlanta, Georgia, United States
Dunwoody Pediatrics & Children's Healthcare of Atlanta
Dunwoody, Georgia, United States
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana, United States
Unnamed facility
Fort Wayne, Indiana, United States
Boston Children's Hospital
Boston, Massachusetts, United States
Henry Ford Health System
Detroit, Michigan, United States
Hudson Valley Oncology Hematology
Hawthorne, New York, United States
Weill Cornell Medical College
New York, New York, United States
Children's Hospital at Montefiore
The Bronx, New York, United States
Cincinnati Children's Hospital
Cincinnati, Ohio, United States
...and 46 more locations